| Active Not Recruiting | A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclob Pharmakokinetic, Open Label, Phase 1 | Phase 1 | 2025-12-09 |
| Terminated | Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED S Cocaine Use, Cocaine Intoxication, Cocaine Toxicity | Phase 2 | 2024-08-16 |
| Completed | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate th Phase 1 First-in-human Study Involving Healthy Subjects | Phase 1 | 2023-07-18 |
| Completed | Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) Depression, Depressive Disorder, Depressive Symptoms | Phase 2 | 2023-03-02 |
| Completed | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura | Phase 2 | 2022-12-06 |
| Withdrawn | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD PTSD | Phase 2 | 2022-10-14 |
| Completed | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID | Phase 2 | 2022-08-18 |
| Completed | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia Fibromyalgia | Phase 3 | 2022-04-06 |
| Completed | A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Healthy Subjects (HS) | Phase 1 | 2022-03-18 |
| Terminated | Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2 | Phase 1 | 2022-01-07 |
| Withdrawn | An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alo Cocaine Intoxication | Phase 2 | 2021-09-03 |
| Completed | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia Fibromyalgia | Phase 3 | 2020-07-22 |
| Completed | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia Fibromyalgia | Phase 3 | 2019-12-09 |
| Completed | Dose-Proportionality and Food Effect Study of TNX-102 SL Healthy Subjects | Phase 1 | 2019-10-14 |
| Terminated | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD PTSD | Phase 3 | 2019-03-07 |
| Completed | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD PTSD | Phase 3 | 2018-04-19 |
| Completed | Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules Healthy Subjects | Phase 1 | 2018-01-29 |
| Terminated | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients PTSD | Phase 3 | 2017-06-20 |
| Terminated | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD PTSD | Phase 3 | 2017-03-27 |
| Terminated | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patient Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases | Phase 3 | 2016-07-22 |
| Completed | Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. Healthy Adults | Phase 1 | 2015-12-16 |
| Completed | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients Primary Fibromyalgia | Phase 3 | 2015-08-04 |
| Completed | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache Tension-Type Headache | Phase 2 | 2015-06-01 |
| Completed | Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Cond PTSD | Phase 2 | 2015-04-14 |
| Completed | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibR Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases | Phase 3 | 2015-04-01 |
| Completed | Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers Healthy | Phase 1 | 2014-11-01 |
| Completed | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions PTSD | Phase 2 | 2014-10-01 |
| Completed | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients Primary Fibromyalgia | Phase 3 | 2013-12-01 |
| Completed | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) Primary Fibromyalgia | Phase 2 / Phase 3 | 2013-09-01 |
| Completed | Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenz Healthy Adults | Phase 1 | 2013-06-01 |
| Completed | Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adult Healthy Adults | Phase 1 | 2012-09-01 |
| Completed | Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults Healthy Adults | Phase 1 | 2012-06-01 |
| Completed | A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy | Phase 1 | 2011-11-18 |